Chromadex Corp (CDXC) 1.0800 $CDXC
ChromaDex Secures $5.0 Million in Growth Capital Financing from Hercules
PR Newswire - Tue Sep 30, 5:30AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it closed on a $5.0 million growth capital debt financing from Hercules Technology Growth Capital (NYSE: HTGC). The financing will provide ChromaDex with additional working capital to support its rapidly-growing ingredient business, as well as accelerate the Company's research and development efforts.
University of California Irvine Completes Pterostilbene Study For Prevention of Skin Damage from UV Exposure
PR Newswire - Mon Sep 22, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the completion of an animal skincare study of pterostilbene by researchers at The University of California Irvine (UCI).
ChromaDex and Healthy Directions enter into NIAGEN(TM) Supply Agreement
PR Newswire - Thu Sep 11, 7:20AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has entered into an ingredient supply agreement with Healthy Directions, a direct-to-consumer nutritional supplement retailer and wholly-owned subsidiary of Helen of Troy Limited (NASDAQ: HELE).
ChromaDex Names Additional Scientific Advisory Board Members
PR Newswire - Thu Sep 04, 7:20AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today it has appointed three highly respected scientists and researchers to the company's recently formed Scientific Advisory Board (SAB): Dr. Charles Brenner, Dr. Rob Beudeker, and Dr. Bruce German.
ChromaDex® Reports Second Quarter Ingredient Sales Grew 155% Year-Over-Year and 52% Sequentially
PR Newswire - Tue Aug 12, 7:25AM CDT
ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the quarter ended June 28, 2014.
ChromaDex's Ryan Dellinger to Speak at 248th American Chemical Society National Meeting
PR Newswire - Wed Aug 06, 9:07AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that Ryan Dellinger, Ph.D., director of scientific affairs at ChromaDex, will speak at the 248th American Chemical Society National Meeting on August 10-14.
ChromaDex® CEO to Present at 34th Annual Canaccord Genuity Growth Conference on August 13th at 8:30 am EDT
PR Newswire - Tue Aug 05, 7:30AM CDT
ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 34th Annual Canaccord Genuity Growth Conference to be held at the Intercontinental Boston.
ChromaDex Signs Material Transfer Agreement With Prominent Australian Research Institute for NIAGEN(TM) Research
PR Newswire - Thu Jul 31, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with Murdoch Childrens Research Institute, the preeminent child health research institute in Australia. ChromaDex will provide Murdoch Childrens Research Institute with quantities of its proprietary NIAGEN(TM) nicotinamide riboside (NR) ingredient for research use.
ChromaDex Initiates First Human Clinical Study to Confirm ChromaDex's NIAGEN(TM) Nicotinamide Riboside Will Increase NAD+
PR Newswire - Wed Jul 16, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the first human clinical study for its patented ingredient NIAGEN(TM), the first and only commercially available form of nicotinamide riboside (NR). The study will engage the laboratory of Dr. Charles Brenner, Roy J. Carver Chair of Biochemistry and Professor of Internal Medicine at University of Iowa. Brenner, is credited with discovery of NR as a vitamin in organisms from yeast to people as published in Cell in 2004.
Nobel Laureate Roger Kornberg to Chair New ChromaDex Scientific Advisory Board
PR Newswire - Tue Jul 08, 7:20AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has appointed Nobel Laureate Roger Kornberg to Chair the Company's newly formed Scientific Advisory Board ("SAB"
.
ChromaDex to evaluate natural product libraries in research partnership with St Jude Children's Research Hospital
M2 - Fri Jun 20, 7:32AM CDT
Natural products company ChromaDex (Other OTC:CDXC) revealed on Thursday that it intends to evaluate its natural product libraries in a research based partnership with St Jude Children's Research Hospital.
ChromaDex Signs Collaboration Research Agreement with St. Jude Children's Research Hospital
PR Newswire - Thu Jun 19, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with St. Jude Children's Research Hospital to evaluate ChromaDex's natural product libraries.
Thorne Research Introduces a New Product, NiaCel(TM), Featuring NIAGEN(TM), To Support Healthy Aging
PR Newswire - Wed Apr 02, 7:30AM CDT
Thorne Research today announced the launch of NiaCel(TM), an innovative nutritional supplement that supports endurance, energy, and healthy aging. NiaCel(TM) is one of the first commercially available products to feature the ingredient NIAGEN(TM) from ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries.
ChromaDex® Reports 2013 Full-Year Results
PR Newswire - Thu Mar 27, 5:45AM CDT
ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the year ended December 28, 2013.
ChromaDex Signs Material Transfer Agreement With Leading Dutch University for NIAGEN(TM) Research
PR Newswire - Wed Mar 12, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Groningen Biomolecular Sciences & Biotechnology Institute (GBB), a leading research institute at the University of Groningen in the Netherlands. ChromaDex will provide GBB with quantities of its proprietary NIAGEN(TM) nicotinamide riboside (NR) ingredient.
ChromaDex to Present at the 26th Annual ROTH Conference on March 10th at 4:30 pm PDT
PR Newswire - Thu Mar 06, 7:20AM CST
ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 26th Annual ROTH Conference, which will take place from March 9-12 at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Feb 27, 8:59AM CST
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, February 27, 2014 at 10:00 p.m. Pacific (1 a.m. EST). The show will also air on Bloomberg U.K. Saturday, March 1, 2014 at 12:30 a.m. GMT; on Bloomberg Europe Sunday, March 2, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday March 2, 2014 at 3:30 p.m. HKT.
Public Outcry Over Mavuno Church "Gerrit" Poster
by Khikami Obbayi - All Africa Global Media - Wed Feb 26, 12:01AM CST
The Mavuno Church over the weekend put up a controversial poster which has been trending on Social Media as people weigh in on the debate of the appropriateness of the poster's design. The poster which is an advert for a series of sermons to be held during services for the month of March incorporates a picture of would be teens in a presumably intimate position together with titles to secular songs including a controversial book title.
ChromaDex CEO to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference on Wednesday, January 22nd at 8:30 am EST
PR Newswire - Fri Jan 17, 7:30AM CST
ChromaDex Corp.® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at "TEN," Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida in Room 2 on Wednesday, January 22, 2014 at 8:30 am EST.
International Stevia Council and ChromaDex Enter Into Agreement for Reference Benchmark Standard
PR Newswire - Wed Dec 18, 7:25AM CST
The International Stevia Council (ISC) and ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, have entered into an agreement whereby ChromaDex is to provide, for the next two years, the Reference Benchmark Standard in the ISC's Proficiency Testing Program (PTP) for stevia leaf extracts.
ChromaDex Secures $5.0 Million in Growth Capital Financing from Hercules
PR Newswire - Tue Sep 30, 5:30AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it closed on a $5.0 million growth capital debt financing from Hercules Technology Growth Capital (NYSE: HTGC). The financing will provide ChromaDex with additional working capital to support its rapidly-growing ingredient business, as well as accelerate the Company's research and development efforts.
University of California Irvine Completes Pterostilbene Study For Prevention of Skin Damage from UV Exposure
PR Newswire - Mon Sep 22, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the completion of an animal skincare study of pterostilbene by researchers at The University of California Irvine (UCI).
ChromaDex and Healthy Directions enter into NIAGEN(TM) Supply Agreement
PR Newswire - Thu Sep 11, 7:20AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has entered into an ingredient supply agreement with Healthy Directions, a direct-to-consumer nutritional supplement retailer and wholly-owned subsidiary of Helen of Troy Limited (NASDAQ: HELE).
ChromaDex Names Additional Scientific Advisory Board Members
PR Newswire - Thu Sep 04, 7:20AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today it has appointed three highly respected scientists and researchers to the company's recently formed Scientific Advisory Board (SAB): Dr. Charles Brenner, Dr. Rob Beudeker, and Dr. Bruce German.
ChromaDex® Reports Second Quarter Ingredient Sales Grew 155% Year-Over-Year and 52% Sequentially
PR Newswire - Tue Aug 12, 7:25AM CDT
ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the quarter ended June 28, 2014.
ChromaDex's Ryan Dellinger to Speak at 248th American Chemical Society National Meeting
PR Newswire - Wed Aug 06, 9:07AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that Ryan Dellinger, Ph.D., director of scientific affairs at ChromaDex, will speak at the 248th American Chemical Society National Meeting on August 10-14.
ChromaDex® CEO to Present at 34th Annual Canaccord Genuity Growth Conference on August 13th at 8:30 am EDT
PR Newswire - Tue Aug 05, 7:30AM CDT
ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 34th Annual Canaccord Genuity Growth Conference to be held at the Intercontinental Boston.
ChromaDex Signs Material Transfer Agreement With Prominent Australian Research Institute for NIAGEN(TM) Research
PR Newswire - Thu Jul 31, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with Murdoch Childrens Research Institute, the preeminent child health research institute in Australia. ChromaDex will provide Murdoch Childrens Research Institute with quantities of its proprietary NIAGEN(TM) nicotinamide riboside (NR) ingredient for research use.
ChromaDex Initiates First Human Clinical Study to Confirm ChromaDex's NIAGEN(TM) Nicotinamide Riboside Will Increase NAD+
PR Newswire - Wed Jul 16, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the first human clinical study for its patented ingredient NIAGEN(TM), the first and only commercially available form of nicotinamide riboside (NR). The study will engage the laboratory of Dr. Charles Brenner, Roy J. Carver Chair of Biochemistry and Professor of Internal Medicine at University of Iowa. Brenner, is credited with discovery of NR as a vitamin in organisms from yeast to people as published in Cell in 2004.
Nobel Laureate Roger Kornberg to Chair New ChromaDex Scientific Advisory Board
PR Newswire - Tue Jul 08, 7:20AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has appointed Nobel Laureate Roger Kornberg to Chair the Company's newly formed Scientific Advisory Board ("SAB"
. ChromaDex to evaluate natural product libraries in research partnership with St Jude Children's Research Hospital
M2 - Fri Jun 20, 7:32AM CDT
Natural products company ChromaDex (Other OTC:CDXC) revealed on Thursday that it intends to evaluate its natural product libraries in a research based partnership with St Jude Children's Research Hospital.
ChromaDex Signs Collaboration Research Agreement with St. Jude Children's Research Hospital
PR Newswire - Thu Jun 19, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with St. Jude Children's Research Hospital to evaluate ChromaDex's natural product libraries.
Thorne Research Introduces a New Product, NiaCel(TM), Featuring NIAGEN(TM), To Support Healthy Aging
PR Newswire - Wed Apr 02, 7:30AM CDT
Thorne Research today announced the launch of NiaCel(TM), an innovative nutritional supplement that supports endurance, energy, and healthy aging. NiaCel(TM) is one of the first commercially available products to feature the ingredient NIAGEN(TM) from ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries.
ChromaDex® Reports 2013 Full-Year Results
PR Newswire - Thu Mar 27, 5:45AM CDT
ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the year ended December 28, 2013.
ChromaDex Signs Material Transfer Agreement With Leading Dutch University for NIAGEN(TM) Research
PR Newswire - Wed Mar 12, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Groningen Biomolecular Sciences & Biotechnology Institute (GBB), a leading research institute at the University of Groningen in the Netherlands. ChromaDex will provide GBB with quantities of its proprietary NIAGEN(TM) nicotinamide riboside (NR) ingredient.
ChromaDex to Present at the 26th Annual ROTH Conference on March 10th at 4:30 pm PDT
PR Newswire - Thu Mar 06, 7:20AM CST
ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 26th Annual ROTH Conference, which will take place from March 9-12 at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Feb 27, 8:59AM CST
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, February 27, 2014 at 10:00 p.m. Pacific (1 a.m. EST). The show will also air on Bloomberg U.K. Saturday, March 1, 2014 at 12:30 a.m. GMT; on Bloomberg Europe Sunday, March 2, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday March 2, 2014 at 3:30 p.m. HKT. Public Outcry Over Mavuno Church "Gerrit" Poster
by Khikami Obbayi - All Africa Global Media - Wed Feb 26, 12:01AM CST
The Mavuno Church over the weekend put up a controversial poster which has been trending on Social Media as people weigh in on the debate of the appropriateness of the poster's design. The poster which is an advert for a series of sermons to be held during services for the month of March incorporates a picture of would be teens in a presumably intimate position together with titles to secular songs including a controversial book title.
ChromaDex CEO to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference on Wednesday, January 22nd at 8:30 am EST
PR Newswire - Fri Jan 17, 7:30AM CST
ChromaDex Corp.® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at "TEN," Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida in Room 2 on Wednesday, January 22, 2014 at 8:30 am EST.
International Stevia Council and ChromaDex Enter Into Agreement for Reference Benchmark Standard
PR Newswire - Wed Dec 18, 7:25AM CST
The International Stevia Council (ISC) and ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, have entered into an agreement whereby ChromaDex is to provide, for the next two years, the Reference Benchmark Standard in the ISC's Proficiency Testing Program (PTP) for stevia leaf extracts.
